Podcasts about colorectal

Dr. Sumanta (Monty) Pal and Dr. Kimmie Ng discuss the disturbing rise of early-onset gastrointestinal cancers, the unique challenges faced by younger patients, and key research that is shedding light on potential drivers of early diagnoses in colorectal cancer. TRANSCRIPT Dr. Sumanta (Monty) Pal: Hello, everyone. I'm Dr. Monty Pal, and I'm a medical oncologist and professor and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. I'm really delighted to welcome you all to the ASCO Daily News Podcast as the show's new host. I'll be bringing you discussions with leaders in the oncology space on a variety of topics. I've been working hard with the ASCO team on picking the ideal topics to bring to you, and I'm really delighted to introduce my first guest, a dear friend, Dr. Kimmie Ng, to discuss this huge problem that we're seeing nowadays of early-onset GI cancers. Dr. Ng is the associate chief of the Division of Gastrointestinal Oncology at the Dana-Farber Cancer Institute, and she's an associate professor of medicine at Harvard Medical School in Boston. She serves as co-director of the Colon and Rectal Cancer Program. She's also the founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber. I'm sure we'll talk a little bit about that today.  Just to note, our full disclosures are available in the transcript of this episode.  Dr Ng, it's so great to have you on the podcast. Thanks so much for joining us. Dr. Kimmie Ng: Thank you so much for having me. It's great to be here. Dr. Sumanta (Monty) Pal: I'm going to refer to you as Kimmie, if you don't mind, for the rest of the podcast here. Please, we'll go by first names, if you don't mind.  Your research has really done so much to help improve our understanding of early-onset GI cancers. You've done a lot of work to increase awareness in this space. I don't think there's a couple of months that passes by when I don't see you on television on Good Morning America or other shows really broadcasting this really critical message. I think there's a certain sensitivity that we all have to this issue, right? I mean, because receiving a cancer diagnosis at any age is very challenging, but I'm sure that young patients who face a colorectal cancer diagnosis have some very unique challenges. Could you give us a sense of some of those? Dr. Kimmie Ng: I think the other reason why so many people are interested in this and feel touched by this is that it's not just gastrointestinal cancers that are increasing in young people, but actually a multitude of different cancers have been rising in young individuals. And while it is difficult at any age to receive a cancer diagnosis, we do all know that young people getting a diagnosis like this do face unique challenges. Studies have shown that over 80% have children under the age of 18 when they are diagnosed with colorectal cancer, for example, under the age of 50. And many experience career and education disruptions. They are in what we call the ‘sandwich generation,' where they're not only taking care of young families or starting to think about starting a young family, but they're also taking care of elderly parents. So it's just a very busy stage of life, and to then be facing a usually terminal cancer diagnosis, it is extremely challenging. The other factors that we've seen that seem to be unique or more prevalent in young patients is that there are higher levels of psychosocial distress, depression, and anxiety, and a majority of patients do need medical attention and treatment for those things, whether it's medication treatment or whether it's counseling or support from psychosocial oncologists. And so the other big issue is fertility. We know that so many of the treatments that these young patients receive do permanently and negatively impact fertility. And for a person who is young, who may still be trying to expand their family or again start a family, it is very important that these young patients do receive counseling about fertility preservation prior to starting treatment. Dr. Sumanta (Monty) Pal: You know, it's so interesting you bring this up, and I think about a patient who's in their 40s diagnosed with this disease. They're in the same demographic as I am, as you are. You know, I'm 44 years old, and you know, I'm thinking about my 11- and 12-year-old and my aging parents, right? I mean, the dilemmas that you highlighted are precisely what I'm facing in life, and it's so true, right? If I had to take my day-to-day and superimpose on that a colorectal cancer diagnosis, it would just be problematic in so many spheres, so many spheres. Dr. Kimmie Ng: Absolutely. And because we did think going into this, starting our Young-Onset Colorectal Cancer Center, that these patients will need unique supports, we did conduct a qualitative study and held some focus groups of young-onset colorectal cancer patients as well as their caregivers. And we really identified four primary themes that I think reflect a lot of the experience of patients with cancer, no matter what type of cancer when they're diagnosed young. And the first is the need, feeling overwhelmed by the healthcare system, and the need for patient navigation. As we know, a lot of these patients are previously healthy before they're facing this very serious diagnosis. The second is the need for peer-to-peer support, where they really value connecting with other young patients going through a similar experience. The third, we talked about already, the need for kind of formal psychosocial support in the form of psychosocial oncologists or psychiatrists or social workers. And the last is an interest in research. They are really very invested in getting germline genetic testing as well as somatic genomic profiling to help guide their therapy. Dr. Sumanta (Monty) Pal: That's really encouraging to hear that they themselves are interested in participating in research. I mean, obviously, that's a great way to move the field forward. I view your area of work here as being such a vexing problem because no matter what way you slice it, young-onset colorectal cancer still remains a relatively small proportion of all diagnoses. So how do you go about studying this phenomenon? I mean, it must be challenging to really sort of investigate underlying causes when ostensibly this is still a small piece of the pie. Dr. Kimmie Ng: That is such a great question and is one of the challenges me and my research team think about every single day. As you mentioned, one of the major barriers is that although these cancers are rising in young people, the absolute number of patients being diagnosed is still relatively small, and if it's going to take large scale epidemiologic studies to really understand, for example, what the dietary and lifestyle risk factors are, you need a considerable number of patients in order to have enough power to reach definitive conclusions.  And so this is where it is so important to collaborate. Any single institution is not going to see enough young-onset patients with colorectal cancer to be able to do this work on their own. And so I have really been intent on establishing an international prospective cohort study of patients with young-onset colorectal cancer so that we can increase the numbers of patients we partner with to try to answer these questions, but also so that we can study this on a global scale, because unfortunately this is not something that's just plaguing the United States. It is actually happening in multiple countries around the world. So that is one barrier.  The second, I would say, is that we think it's early life exposures to whatever environmental factor it is that's causing the rise that is likely contributing the most. And so if you imagine how difficult it would be to start studying individuals from when they're children through adolescence, through adulthood, and then all the way until a cancer diagnosis is obtained, a study like that would take too long, would cost too much, and really wouldn't be feasible. So we need to think of alternative ways to really try and answer this question of what is driving this rise in young-onset colorectal cancer. Dr. Sumanta (Monty) Pal: Honestly, Kimmie, this seems like almost an unfair question in the context of what you just mentioned, the challenges in terms of ascertaining causality, right? I'll tell you, I cheated a little bit ahead of this podcast. Kimmie and I had dinner together in Los Angeles a couple months ago. She came out to deliver a Presidential Lectureship at City of Hope. We were delighted to have her. And we did have a couple of thoughts exchanged over potential drivers of these early diagnoses, leaning on perhaps one of the things that you and I are both interested in, the microbiome. But amongst all these things, vitamin D, microbiome, etc., and I won't hold you to this, do you have at least a general sense of what might be contributing to this early-onset phenomenon? Dr. Kimmie Ng: Yeah, as we talked about during my visit there to City of Hope, we do hypothesize that it is a complex interaction between our exposome, which is everything we are exposed to in our environment, which does include diet and lifestyle factors, interacting with host immunity and antitumor immunity, and as well as the microbiome and shaping the composition and diversity of the gut microbiome that are likely interacting to increase susceptibility to colorectal cancer at a younger age. And I will say one of the biggest discoveries, if you will, about what might be driving young-onset colorectal cancer was published a few months ago in Nature. And that paper identified a specific mutational signature caused by the genotoxin colibactin, which is often produced by an organism called pks+ E. coli, as being much more prevalent in younger patients with colorectal cancer than older patients. And so while it doesn't explain necessarily all of young-onset colorectal cancer and why it's rising, it does give us a clue that the microbiome is likely very important in perhaps why this is rising in young people. Dr. Sumanta (Monty) Pal: After you mentioned it, I went back and dove deep into that paper. I was fascinated, fascinated by the content there. And this is just a massive exploration across thousands of patients worldwide. So, I mean, if there is a way to get at least some hint of what's driving this phenomenon, I suppose that's it. So thank you for pointing me in the direction of that manuscript. Now that we've addressed the issue of diagnosis, if we could just, you know, verge on the topic of treatment, right? And this is something that I struggle with. When I have my young patients with kidney cancer, I don't know necessarily that my treatment paradigm changes a whole heck of a lot. I guess what I will say is I might be a little bit more aggressive about concepts like definitive management with surgery. I suppose perhaps their treatment tolerance is a little bit higher. But tell us about the setting of young-onset colorectal cancer. Is the philosophy any different in terms of the actual sort of management of these patients? Dr. Kimmie Ng: That's a great question, and actually I was honored to participate in the first international consensus guidelines group to try to come up with uniform recommendations for how to treat young patients with colorectal cancer. And you know, the overall consensus is just as you said, the medical care of these young patients right now is really not that much different than that of an older patient with colorectal cancer. There are a couple of distinctions. One is that all young patients should get germline genetic testing, given that there is a higher prevalence of pathogenic germline variants when you are diagnosed at a young age. And the second is what we've already talked about, which is that all young patients should be referred for counseling about fertility preservation prior to starting treatment. But otherwise, the chemotherapy regimens recommended, you know, surgery, radiation, all of that seems very similar to older patients. I will say that because most of our young patients with colorectal cancer are diagnosed with left-sided cancers, including rectal cancers, where some of the treatment may be morbid and result in lifelong complications, we do consider de-escalation of therapy and try to consider the long-term implications when it's safe to do so and won't compromise outcomes. The other concerning thing is that younger patients don't necessarily have a better prognosis than older patients. And multiple studies have shown this, that even though we both often treat younger patients more aggressively – they more often receive multi-agent chemotherapy, and more often undergo surgery and radiation – their survival is not necessarily correspondingly better than an older patient with colorectal cancer. So that suggests to us that maybe these cancers are indeed biologically different and perhaps more aggressive or perhaps less responsive to treatment. And so that is some of the focus of our research too, to understand what is actually different about these cancers and how they respond to treatment. Dr. Sumanta (Monty) Pal: It's such a paradox, isn't it, right? Because you just brought this to my mind. I guess on the one hand, our younger patients may be able to tolerate perhaps a greater amount of chemotherapy, targeted therapy, etc. But you're absolutely right. I mean, they do sort of have these lingering issues with side effects that may persist for much longer than the 80- or 90-year-old that we're treating in the clinic. I mean, these tend to be sort of lifelong consequences and sequelae that they're dealing with. So that really does evolve to be a challenge. You've kind of changed my mindset there a little bit. Dr. Kimmie Ng: Yeah, I do think survivorship issues and long-term complications of therapy do need to be considered, especially for a young person who we hope will live a very, very long time. And so part of the work that our Young-Onset Colorectal Cancer Center is doing, we are participating in a pilot navigation study where we navigate patients to survivorship earlier than we typically would, perhaps, for an older patient. And that's so we can get a head start on addressing some of those potential complications of therapy and hopefully mitigate them so that they don't become an issue long term. Dr. Sumanta (Monty) Pal: Do you think there's a role for de-escalation studies formally in these young populations of patients? Dr. Kimmie Ng: I think de-escalation studies are important overall, and specifically for locally advanced rectal cancer, which again is one of the most common types of colorectal cancer diagnosed in our young patients, there are certain populations that may be able to forgo the radiation treatment to the pelvis, for example, and there's more and more patients who now may become candidates for non-operative management where they may not necessarily need to have their rectal cancer surgically removed. And elimination potentially of both of those modalities of treatment can really avoid some of the most serious and morbid complications that often occur with these treatments. Dr. Sumanta (Monty) Pal: Really interesting. Now, this is not and will never be a political podcast, but you know, obviously we're dealing with the consequences of changes on funding and so forth that have evolved over time. And I think it's worth sort of speculating how the landscape of research may change on account of that. Could you comment perhaps a little bit on how some of the funding cuts that we've seen recently at the NIH might affect the body of work that you're so integrally involved in? Dr. Kimmie Ng: I am honestly very worried about the current funding environment. Colorectal cancer is the third most commonly diagnosed cancer among men and women in the United States and globally, and when you combine men and women together, the second leading cause of cancer death. But proportionally, we receive much less funding for colorectal cancer compared to other cancer types. And my thoughts have always been that perhaps this is because there is this stigma around colorectal cancer and maybe some of the symptoms associated with colorectal cancer. And so on top of that, to have additional challenges in obtaining funding, I worry what it will do to the pace of progress for especially young patients with this disease. Also, because of some new stipulations that perhaps international collaborations are being discouraged, I also worry about that aspect of it because young-onset colorectal cancer and gastrointestinal cancers in general is a global phenomenon happening in multiple countries around the world. And if we are to understand what the environmental factors are affecting the different rates of rise in these different countries, we do so much need that international collaboration. So yes, I am worried, and I do hope that conversations like this will spark an awareness of the need for more funding and continued funding into this disease. Dr. Sumanta (Monty) Pal: I will say that, and the audience can't see this because this is an audio program, but I'm wearing my Southwest Oncology shirt here, a SWOG, and it's one of the National Cancer Institute-funded cooperative groups. And you know, I was recently dismayed to find that, you know, funding got cut for international collaborations and enrollment in South America and Latin America. And this was traditionally actually a mainstay of our enrollment for many trials, including trials in rare cancers that present themselves in younger patients in the GU space. So, I completely agree with you. We've got to do something to address this funding issue to make sure that this body of work, both yours and mine, continues, without a doubt. Kimmie, this has been a delightful conversation. I really want to thank you for, you know, leading the charge in the young-onset colorectal cancer space, and you've done so much tremendous work here. Dr. Kimmie Ng: Thank you for having me. Dr. Sumanta (Monty) Pal: If you value the insights that you hear on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. And again, thank you for joining us today. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:   Dr. Sumanta (Monty) Pal @montypal Dr. Kimmie Ng @KimmieNgMD Follow ASCO on social media:    @ASCO on Twitter   ASCO on Bluesky  ASCO on Facebook    ASCO on LinkedIn    Disclosures:   Dr. Sumanta (Monty) Pal: Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis Dr. Kimmie Ng: Honoraria: Seagen, GlaxoSmithKline Consulting or Advisory Role: CytomX Therapeutics, Jazz Pharmaceuticals, Revolution Medicines, Abbvie, Bayer, Pfizer, Agenus, Johnson & Johnson/Janssen, Etiome, AstraZeneca Research Funding (Inst.): Pharmavite, Janssen Other Relationship: JAMA

Dr. Mira Slizovsky will discuss the most common reasons parents consider giving supplements to their children and advice on when they might be needed.

In today's episode, we'll be diving into the world of colorectal health, breaking down both functional conditions like pelvic floor disorders and chronic constipation, and biological conditions such as colorectal cancer, inflammatory bowel disease, and more. Dr Chris Gillespie shares his personal journey into the field of colorectal surgery, and we take a behind the scenes look at what patients can expect when referred to a colorectal surgeon, such asDr Chris Gillespie, from diagnosis and non-surgical treatments to surgical approaches. Dr Chris Gillespie walks us through the step by step process of care.- We'll also bust some common myths, explore preventative tips for maintaining colorectal health, and talk about exciting innovations in the future of his speciality. So whether you're curious, concerned or just keen to learn more, this episode is full of insights you won't want to miss. Please enjoy my conversation with Dr Chris Gillespie.

We are joined by Dr. Joanne Favuzza of Capital District Colon & Rectal Surgery Associates, a practice of St. Peter's Health Partners Medical Associates. Joe Donahue hosts.

“Colorectal cancer treatment is not just about eliminating a disease. It's about preserving life quality and empowering patients through every phase. So I think nurses are really at the forefront that we can do that in the oncology nursing space. So from early detection to survivorship, the journey is deeply personal. Precision medicine, compassionate care, and informed decision-making are reshaping outcomes. Treatment's just not about protocols. It's about people,” ONS member Kris Mathey, DNP, APRN-CNP, AOCNP®, gastrointestinal medical oncology nurse practitioner at The James Cancer Hospital of The Ohio State University Wexner Medical Center in Columbus, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about colorectal cancer treatment.  Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 1.0 contact hour of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by August 1, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learner will report an increase in knowledge related to the treatment of colorectal cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 370: Colorectal Cancer Screening, Early Detection, and Disparities Episode 153: Metastatic Colorectal Cancer Has More Treatment Options Than Ever Before ONS Voice articles: Colorectal Cancer Prevention, Screening, Treatment, and Survivorship Recommendations Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer) How Liquid Biopsies Are Used in Cancer Treatment Selection Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin What Is a Liquid Biopsy? Clinical Journal of Oncology Nursing article: Colorectal Cancer in Young Adults: Considerations for Oncology Nurses Oncology Nursing Forum article: Neurotoxic Side Effects Early in the Oxaliplatin Treatment Period in Patients With Colorectal Cancer ONS Colorectal Cancer Learning Library ONS Biomarker Database (filtered by colorectal cancer) ONS Peripheral Neuropathy Symptom Interventions American Cancer Society colorectal cancer resources CancerCare Colorectal Cancer Alliance Colorectal Cancer Resource and Action Network Fight Colorectal Cancer National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode “Colorectal cancer has several different types, but there is one that dominates the landscape, and that is adenocarcinoma. So I think most of us have heard that. It's fairly common, and it accounts for about 95% of all colorectal cancers. It begins in the glandular cells lining the colon or rectum and often develops from polyps, in particular adenomatous polyps.” TS 1:41 “One of the biomarkers that we'll most commonly hear about is KRAS or NRAS mutations. This indicates tumor genetics, and these mutations suggest resistance to our EGFR inhibitors such as cetuximab. BRAF mutation or V600E is a more aggressive tumor subtype, and those may respond to our BRAF targeted therapy. … And then our MSI-high or MMR-deficient—microsatellite instability or mismatch repair deficiency—that really predicts an immunotherapy response and may indicate Lynch syndrome, which is a huge genetic component that takes a whole other level of counseling and genetic testing with our patients as well.” TS 6:02 “Polypectomy or a local excision—that removes our small tumors or polyps during that colonoscopy. And that's what's used for those stage 0 or early stage I cancers. A colectomy removes part or all of the colon. This may be open or laparoscopic. It can include a hemicolectomy, a segmental resection, or a total colectomy, so where you take out the entire part of the colon. A proctectomy removes part or all of the rectum. This may include a low anterior resection, also known as an LAR … or an abdominal perineal resection, which is an APR. … Colostomy or ileostomy—that diverts the stool to an external bag via stoma. Sometimes this is temporary or permanent depending on the type of surgery.” TS 14:11 “We'll have our patients say, ‘Hey, I want immunotherapy therapy. I see commercials on it that it works so well.' We have to make sure that these patients are good candidates for it, also that we're treating them adequately. We need to make sure that they have those biomarkers, so as I mentioned, the MSI-high or MMR tumors. Our MSS-stable tumors—they may benefit from newer combinations or clinical trials. Metastatic disease—immunotherapy may be used alone or with other treatments. And then in the neoadjuvant setting, some trials are really showing promising results using immunotherapy prior to surgery.” TS 25:38 “Antibody-drug conjugates are really an exciting frontier in all cancer treatments as well as colorectal cancer treatment. This is used mainly for patients with advanced or treatment-resistant disease, and these therapies combine the targeted power of monoclonal antibodies with the cell-killing ability of potent chemotherapy agents. They're still on the horizon for the most part in colorectal cancer. However, there is only one approved antibody-drug conjugate, or ADC, at this time, and that's trastuzumab deruxtecan, or Enhertu. That's approved for any solid tumor, such as colorectal cancer with HER2 IHC 3+. So again, looking back at that pathology in those markers, making sure that you have that HER2 mutation and that IHC.” TS 35:00 “There are a few myths going around about colorectal cancer treatment that can lead to confusion or even delayed care. One myth is only older men get colorectal cancer. As you heard me talk in my previous podcast on screening, unfortunately, this isn't necessarily true. Colorectal cancer affects both men and women and our cases in the younger population are rising. So our screening guidelines have changed to age 45 because we are seeing it in the younger population.” TS 45:54

There has been a marked increase in bowel cancers amongst younger people in Australia, and scientists and doctors are researching to find out what is going on.  

Fecal incontinence is more common than people realize, but patients are often embarrassed to discuss with their doctor. Dr. Reidy discusses causes, diagnosis and treatment options.

In this episode of SurgOnc Today, the SSO Colorectal Disease Site Working Group will recap content from the 2025 American Society of Colorectal Surgeons (ASCARS) and Society of Surgery of the Alimentary Tract (SSAT) programs. Broad highlights of both benign and malignant disease conditions are covered. This episode is hosted by Dr. Jennifer Miller-Ocuin, Dr. Jitesh Patel, Dr. Abhineet Uppal, and Dr. Prakash Pandalai. They cover hot topics, areas of controversy, and new research shared across various specialties including colorectal surgery, surgical oncology, gastroenterology, basic, and translational sciences. We hope you will enjoy this recap.

BUFFALO, NY – July 22, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on July 21, 2025, titled “Statins exhibit anti-tumor potential by modulating Wnt/β-catenin signaling in colorectal cancer.” In this work, led by first author Sneha Tripathi from the Indian Institute of Science Education and Research and corresponding author Sanjeev Galande from the Center of Excellence in Epigenetics at Shiv Nadar University, researchers discovered that statins, widely used to lower cholesterol, may also suppress colorectal cancer growth. This finding highlights a potential new role for these common drugs in cancer prevention and therapy. Colorectal cancer is one of the leading causes of cancer-related deaths worldwide, and new strategies are urgently needed to improve treatment results. Statins, originally developed to lower cholesterol levels, have gained attention for their possible anti-cancer properties. The study investigated how statins affect the Wnt/β-catenin signaling pathway, a critical driver in colorectal cancer development and progression. The researchers discovered that statins disrupt the Wnt/β-catenin signaling pathway, leading to lower levels of tumor-promoting proteins and to cancer-suppressing cellular behaviors. Experiments in both colorectal cell cultures and mouse models confirmed that statins reduced tumor growth without causing noticeable side effects. This study further revealed that statins downregulate SATB1, a protein linked to aggressive tumor behavior, while increasing SATB2, a protein with tumor-suppressing effects. These changes made the cancer cells less able to grow and spread. “This reciprocal regulation shifts cellular phenotypes between epithelial and mesenchymal states in 3D spheroid models.” Overall, the findings suggest that statins could be repurposed to complement existing colorectal cancer treatments or even be used in preventive strategies for high-risk individuals. By targeting the molecular machinery that drives colorectal tumor development, statins offer a promising, accessible, and well-understood option for further research in cancer therapy. This research opens the door to larger clinical studies to explore how best to integrate statins into cancer care. If successful, this approach could provide a cost-effective strategy for reducing the global burden of colorectal cancer, which remains a significant health challenge. DOI - https://doi.org/10.18632/oncotarget.28755 Correspondence to - Sanjeev Galande - sanjeev.galande@snu.edu.in Video short - https://www.youtube.com/watch?v=A95ICULaH3Y Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28755 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, colorectal cancer, statins, SATB1, Wnt/β-catenin signaling, tumor-suppressive phenotype To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The incidence of early onset colorectal cancer (EOCRC) has been rising prompting the change in change in screening guidelines to 45 years of age for average risk patients. Join us for an in-depth discussion with guest speakers Dr. Andrea Cercek and Dr. Nancy You, where we provide a comprehensive look at the growing challenge of EOCRC. Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center - Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian - Dr. Phil Bauer, Graduating Colorectal Surgical Oncology Fellow at Memorial Sloan Kettering Cancer Center  - Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center - Dr. Andrea Cercek - Gastrointestinal Medical Oncologist at Memorial Sloan Kettering Cancer Center - Dr. Y. Nancy You, MD MHSc - Professor, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Learning objectives:  - Describe trends in incidence of colorectal cancer, with emphasis on the rise of EOCRC. - Identify age groups and demographics most affected by EOCRC. - Summarize USPSTF recommendations for colorectal cancer screening. - Distinguish between screening methods (e.g., colonoscopy, FIT-DNA) and their sensitivity. - Understand treatment approaches for colon and rectal cancer (CRC) - Understand the role of mismatch repair (MMR) status in guiding treatment. - Outline the importance of genetic counseling and testing in young patients. - Discuss racial, ethnic, and socioeconomic disparities in CRC incidence and outcomes. - Describe the impact of cancer treatment on fertility and sexual health. -  Review fertility preservation options. - Identify the value of integrated care teams for young CRC patients. References: 1.         Siegel, R. L. et al. Colorectal Cancer Incidence Patterns in the United States, 1974–2013. JNCI J. Natl. Cancer Inst. 109, djw322 (2017). https://pubmed.ncbi.nlm.nih.gov/28376186/ 2.         Abboud, Y. et al. Rising Incidence and Mortality of Early-Onset Colorectal Cancer in Young Cohorts Associated with Delayed Diagnosis. Cancers 17, 1500 (2025). https://pubmed.ncbi.nlm.nih.gov/40361427/ 3.         Phang, R. et al. Is the Incidence of Early-Onset Adenocarcinomas in Aotearoa New Zealand Increasing? Asia Pac. J. Clin. Oncol.https://pubmed.ncbi.nlm.nih.gov/40384533/ 4.         Vitaloni, M. et al. Clinical challenges and patient experiences in early-onset colorectal cancer: insights from seven European countries. BMC Gastroenterol. 25, 378 (2025). https://pubmed.ncbi.nlm.nih.gov/40375142/ 5.         Siegel, R. L. et al. Global patterns and trends in colorectal cancer incidence in young adults. (2019) doi:10.1136/gutjnl-2019-319511. https://pubmed.ncbi.nlm.nih.gov/31488504/ 6.         Cercek, A. et al. A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. J. Natl. Cancer Inst. 113, 1683–1692 (2021). https://pubmed.ncbi.nlm.nih.gov/34405229/ 7.         Zheng, X. et al. Comprehensive Assessment of Diet Quality and Risk of Precursors of Early-Onset Colorectal Cancer. JNCI J. Natl. Cancer Inst. 113, 543–552 (2021). https://pubmed.ncbi.nlm.nih.gov/33136160/ 8.         Standl, E. & Schnell, O. Increased Risk of Cancer—An Integral Component of the Cardio–Renal–Metabolic Disease Cluster and Its Management. Cells 14, 564 (2025). https://pubmed.ncbi.nlm.nih.gov/40277890/ 9.         Muller, C., Ihionkhan, E., Stoffel, E. M. & Kupfer, S. S. Disparities in Early-Onset Colorectal Cancer. Cells 10, 1018 (2021). https://pubmed.ncbi.nlm.nih.gov/33925893/ 10.       US Preventive Services Task Force. Screening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement. JAMA 325, 1965–1977 (2021). https://pubmed.ncbi.nlm.nih.gov/34003218/ 11.       Fwelo, P. et al. Differential Colorectal Cancer Mortality Across Racial and Ethnic Groups: Impact of Socioeconomic Status, Clinicopathology, and Treatment-Related Factors. Cancer Med. 14, e70612 (2025). https://pubmed.ncbi.nlm.nih.gov/40040375/ 12.       Lansdorp-Vogelaar, I. et al. Contribution of Screening and Survival Differences to Racial Disparities in Colorectal Cancer Rates. Cancer Epidemiol. Biomarkers Prev. 21, 728–736 (2012). https://pubmed.ncbi.nlm.nih.gov/22514249/ 13.       Ko, T. M. et al. Low neighborhood socioeconomic status is associated with poor outcomes in young adults with colorectal cancer. Surgery 176, 626–632 (2024). https://pubmed.ncbi.nlm.nih.gov/38972769/ 14.       Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A. & Jemal, A. Colorectal cancer statistics, 2023. CA. Cancer J. Clin. 73, 233–254 (2023). https://pubmed.ncbi.nlm.nih.gov/36856579/ 15.       Jain, S., Maque, J., Galoosian, A., Osuna-Garcia, A. & May, F. P. Optimal Strategies for Colorectal Cancer Screening. Curr. Treat. Options Oncol. 23, 474–493 (2022). https://pubmed.ncbi.nlm.nih.gov/35316477/ 16.       Zauber, A. G. The Impact of Screening on Colorectal Cancer Mortality and Incidence: Has It Really Made a Difference? Dig. Dis. Sci. 60, 681–691 (2015). https://pubmed.ncbi.nlm.nih.gov/25740556/ 17.       Edwards, B. K. et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116, 544–573 (2010). https://pubmed.ncbi.nlm.nih.gov/19998273/ 18.       Cercek, A. et al. Nonoperative Management of Mismatch Repair–Deficient Tumors. New England Journal of Medicine 392, 2297–2308 (2025). https://pubmed.ncbi.nlm.nih.gov/40293177/ 19.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Molecular Heterogeneity in Early-Onset Colorectal Cancer: Pathway-Specific Insights in High-Risk Populations. Cancers 17, 1325 (2025). https://pubmed.ncbi.nlm.nih.gov/40282501/ 20.       Monge, C., Waldrup, B., Carranza, F. G. & Velazquez-Villarreal, E. Ethnicity-Specific Molecular Alterations in MAPK and JAK/STAT Pathways in Early-Onset Colorectal Cancer. Cancers 17, 1093 (2025). https://pubmed.ncbi.nlm.nih.gov/40227607/ 21.       Benson, A. B. et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Cancer Netw. JNCCN 19, 329–359 (2021). https://pubmed.ncbi.nlm.nih.gov/33724754/ 22.       Christenson, E. S. et al. Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancer. https://pubmed.ncbi.nlm.nih.gov/40388545/ 23.       Dasari, A. et al. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. The Lancet 402, 41–53 (2023). https://pubmed.ncbi.nlm.nih.gov/37331369/ 24.       Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). https://pubmed.ncbi.nlm.nih.gov/37142372/ 25.       Sauer, R. et al. Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer. N. Engl. J. Med. 351, 1731–1740 (2004). https://pubmed.ncbi.nlm.nih.gov/15496622/ 26.       Cercek, A. et al. Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. JAMA Oncol. 4, e180071 (2018). https://pubmed.ncbi.nlm.nih.gov/29566109/ 27.       Garcia-Aguilar, J. et al. Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy. J. Clin. Oncol. 40, 2546–2556 (2022). https://pubmed.ncbi.nlm.nih.gov/35483010/ 28.       Schrag, D. et al. Preoperative Treatment of Locally Advanced Rectal Cancer. N. Engl. J. Med. 389, 322–334 (2023). https://pubmed.ncbi.nlm.nih.gov/37272534/ 29.       Kunkler, I. H., Williams, L. J., Jack, W. J. L., Cameron, D. A. & Dixon, J. M. Breast-Conserving Surgery with or without Irradiation in Early Breast Cancer. N. Engl. J. Med. 388, 585–594 (2023). https://pubmed.ncbi.nlm.nih.gov/36791159/ 30.       Jacobsen, R. L., Macpherson, C. F., Pflugeisen, B. M. & Johnson, R. H. Care Experience, by Site of Care, for Adolescents and Young Adults With Cancer. JCO Oncol. Pract. (2021) doi:10.1200/OP.20.00840. https://pubmed.ncbi.nlm.nih.gov/33566700/ 31.       Ruddy, K. J. et al. Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. J. Clin. Oncol. (2014) doi:10.1200/JCO.2013.52.8877. https://pubmed.ncbi.nlm.nih.gov/24567428/ 32.       Su, H. I. et al. Fertility Preservation in People With Cancer: ASCO Guideline Update. J. Clin. Oncol. 43, 1488–1515 (2025). https://pubmed.ncbi.nlm.nih.gov/40106739/ 33.       Smith, K. L., Gracia, C., Sokalska, A. & Moore, H. Advances in Fertility Preservation for Young Women With Cancer. Am. Soc. Clin. Oncol. Educ. Book 27–37 (2018) doi:10.1200/EDBK_208301. https://pubmed.ncbi.nlm.nih.gov/30231357/ 34.       Blumenfeld, Z. How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries. The Oncologist 12, 1044–1054 (2007). 35.       Bhagavath, B. The current and future state of surgery in reproductive endocrinology. Curr. Opin. Obstet. Gynecol. 34, 164 (2022). 36.       Ribeiro, R. et al. Uterine transposition: technique and a case report. Fertil. Steril. 108, 320-324.e1 (2017). 37.       Yazdani, A., Sweterlitsch, K. M., Kim, H., Flyckt, R. L. & Christianson, M. S. Surgical Innovations to Protect Fertility from Oncologic Pelvic Radiation Therapy: Ovarian Transposition and Uterine Fixation. J. Clin. Med. 13, 5577 (2024). 38.       Holowatyj, A. N., Eng, C. & Lewis, M. A. Incorporating Reproductive Health in the Clinical Management of Early-Onset Colorectal Cancer. JCO Oncol. Pract. 18, 169–172 (2022). ***Behind the Knife Colorectal Surgery Oral Board Audio Review: https://app.behindtheknife.org/course-details/colorectal-surgery-oral-board-audio-review Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out our recent episodes here: https://app.behindtheknife.org/listen

In this episode, Therese Markow and Dr. Peter Liang discuss the rise in colorectal cancer among younger people, those below the age of 50. While colorectal cancer is a slow-growing cancer, it is still the third most common cancer for both men and women, and the second leading cause of cancer death in the United States. Due to the trend of decreasing age in colorectal cancer patients, screening guidelines have been lowered to 45, but can be done earlier as needed, based on risk factors. Dr. Liang emphasizes the importance of screening, diet, exercise, and awareness of family history in preventing and detecting colorectal cancer early.     Key Takeaways: Colorectal cancer is the third most common cause of cancer in both men and women. It is the second leading cause of cancer death behind lung cancer. Early-onset colorectal cancer is traditionally defined as occurring in people under age 50. However, there is a rise in people in their 40s, though some (though they are a minority) are in their 20s or 30s. Colorectal cancer is unique due to the number of different tests available for screening for prevention. Colorectal cancer is a slow-growing cancer. A single polyp can sometimes take 10-20 years to develop into cancer. There is no evidence correlating constipation with colorectal cancer. If people want to do juices or fasts or colonics, that is fine, but there is no medical need to do it. If you have symptoms that are concerning, tell your doctor. Sometimes you do need to advocate for yourself to get additional testing.   "Any test that is not a colonoscopy and is abnormal does need to be followed by a colonoscopy. How we prevent Colorectal cancer is by going in with the colonoscopy, removing polyps (which can turn into cancer), or by finding the cancer early, so that your prognosis is much better." —  Dr. Peter Liang   Connect with Dr. Peter Liang: Professional Bio: https://med.nyu.edu/faculty/peter-s-liang  Website: https://med.nyu.edu/research/liang-lab/    Connect with Therese: Website: www.criticallyspeaking.net Threads: @critically_speaking Email: theresemarkow@criticallyspeaking.net     Audio production by Turnkey Podcast Productions. You're the expert. Your podcast will prove it.  

Send us a textStruggling with constipation, diarrhea, or hemorrhoids—and not sure why? In this gut health deep dive, Jessie Wong is joined by colorectal surgeon and Constipation Nation author Dr. Carmen Fong to unpack the real reasons your IBS symptoms might still be flaring up, even when you're doing “everything right.”In This Episode, You'll Learn:✔️ What GLP-1 meds are really doing to your digestion✔️ Constipation fixes that actually work (food, fibre, hydration & more)✔️ Which gut health trends to skip (microbiome tests, detoxes, etc.)Timestamps:[00:00] Intro – Meet Dr. Carmen Fong and today's gut health topics[03:41] GLP-1 medications & gut side effects (constipation, diarrhoea)[11:06] Breaking stigma: why talking about poop matters[19:15] Top tips to relieve constipation without meds[21:18] What to know about haemorrhoids, fissures & rectal health[33:47] Debunking myths: gut microbiome tests, food sensitivity tests & probiotics[53:04] How to properly follow (and not fear) the low FODMAP diet[59:51] Colon cleanses, detoxes & intermittent fasting: helpful or harmful?[01:07:01] Intuitive eating & how restriction leads to food obsessionResources Mentioned:Episode 15Episode 6Episode 17www.carmenfong.comInstagram: Dr. Carmen FongGet Dr. Carmen Fong's book https://carmenfong.com/best-gut-health-book ⭐ Love this episode? Leave us a 5-star review! It helps us reach more people who need IBS support. As a special bonus, I want to give you FREE access to my signature IBS Course. • Leave a review of this podcast • Email a screenshot of your review to info@ibsdietitian.comGet our help:

Colorectal cancer is showing up more often in younger generations, such as millennials. This type of cancer is the second-leading cause of cancer death, but it's also easily preventable with regular screenings. It can be challenging for people in underserved communities to get access to these screenings, or even learn about them, so Mass General Brigham is making an effort to get the word out. Dr. Allison Bryant, MGB's Associate Chief Health Equity Officer, returns to the show this week to share information about this important campaign.

In this episode of the Brown Surgery Podcast, host Dr. Evan Mitchell, MD interviews Dr. Rebecca Gologorsky, MD, one of our colorectal surgeons at Brown Surgery. The conversation dives into Dr. Gologorsky's journey to colorectal surgery, sharing how mentorship and the variety of colorectal procedures—from open to robotic—drew her to the field. Dr. Gologorsky offers practical advice for residents and medical students applying to competitive colorectal fellowships, highlighting the value of research and personal connections. She also touches on emerging tech like single-port surgery and clarifies the colorectal surgeon lifestyle, which can vary from manageable to intense. The episode is perfect for aspiring surgeons curious about the specialty.If anyone has comments on this episode or suggestions for topics please feel free to reach out to me at kenneth_lynch@brown.edu

BUFFALO, NY – June 24, 2025 – A new precision #oncology paper was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment.” In this report, led by Alberto Hernando-Calvo from Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology; Razelle Kurzrock from WIN Consortium and Medical College of Wisconsin; Oncotarget Editor-in-Chief Wafik S. El-Deiry from WIN Consortium and Legorreta Cancer Center at Brown University; and corresponding author Shai Magidi, also from WIN Consortium, along with colleagues, describe the case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. After analysis, the WIN International Molecular Tumor Board proposed different personalized treatment plans based on the tumor's unique genetic mutations. This case highlights the growing role of precision oncology in guiding therapies for patients with treatment-resistant cancers. Colorectal cancer is one of the deadliest cancers worldwide, and managing advanced cases remains a significant challenge. This patient had already received five prior treatment regimens, including chemotherapy and targeted therapies. Although some treatments were initially beneficial, the cancer eventually developed resistance. Molecular analysis revealed key mutations in genes such as BRAF, MET, APC, TP53, and NRAS, which are often linked to aggressive tumor behavior and reduced treatment effectiveness. With limited standard options left, the patient's case was presented and reviewed by the WIN International Molecular Tumor Board, a global panel of cancer experts. The team analyzed the clinical history and genetic profile to design new treatment approaches. These involved off-label drug combinations tailored to the specific mutations found in the tumor. For example, one approach combined trametinib, a drug that blocks cancer cell growth signals, with amivantamab, an antibody that attacks cancer-related proteins MET and EGFR, and regorafenib, which helps cut off blood supply to tumors and may counteract effects from APC and TP53 mutations. “Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily.” This case reflects a shift in cancer care from standardized protocols to precision approaches, where therapy is selected based on a tumor's molecular features. Such strategies aim to delay resistance and slow disease progression more effectively. The WIN International Molecular Tumor Board also discussed practical challenges, including access to medications, combining off-label drugs, and the difficulties of enrolling patients in clinical trials after multiple prior treatments. Although the ultimate treatment decision remained with the patient's physician, this report shows how international collaboration and precision oncology can expand options for patients facing limited alternatives. It also emphasizes the value of repeat genetic analysis during disease progression to monitor new mutations in the tumor that may impact treatment. While the patient ultimately died from cancer progression, this case serves as a model for how molecular analysis and expert input can be used to guide treatment even in complex and metastatic colorectal cancer. As personalized cancer strategies continue to evolve, they may offer potential pathways for patients who have exhausted standard treatment options. DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - shai.magidi@winconsortium.org Video short - https://www.youtube.com/watch?v=uWDtWNgpK7A To learn more about Oncotarget, please visit https://www.oncotarget.com. MEDIA@IMPACTJOURNALS.COM

This week, we present an inspiring episode for anyone interested in the history, present, and future of prostate cancer care. In this Legends in Urology installment of the BackTable Urology Podcast, Dr. Gerald Andriole joins guest host Dr. Niraj Badhiwala to reflect on a career that has left a lasting impact on the field. --- SYNPOSIS Dr. Andriole shares personal stories from his upbringing in Northeastern Pennsylvania and his journey into medicine. He reflects on his expedited education through Penn State and Jefferson Medical College and his path to urology. He discusses his pivotal work in prostate cancer screening, including the influence of major trials like The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial, and traces the evolution of surgical and diagnostic techniques. The conversation also touches on current innovations and the future of prostate cancer management, offering valuable advice for the next generation of urologists. --- TIMESTAMPS 00:00 - Introduction01:59 - From Childhood to Medical School06:48 - Discovering Urology16:52 - Pioneering Prostate Cancer Screening24:07 - The PLCO Study: Design and Challenges28:57 - Controversies and Criticisms in Prostate Cancer Screening33:29 - Evolving Practices in Prostate Cancer Management44:19 - Future of Prostate Cancer Treatment

On la connaît pour ses bienfaits sur les os, mais la vitamine D aurait aussi un rôle à jouer contre le cancer colorectal ... C'est le vrai ou faux de la semaine ! Tous les samedis, retrouvez Flavie Flament en compagnie de Jimmy Mohamed dans l'émission "Ça va beaucoup mieux", votre magazine santé et bien-être.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Health New Zealand is outsourcing more elective operations to private facilities to ease strain on the system. The agency aims to deliver more than 10,500 additional elective procedures by the end of June, by partnering with private hospitals to expand surgical capacity. The target is within reach with more than 8,600 procedures complete since March. Christchurch colorectal and general surgeon Chris Wakeman told Mike Hosking that although he gets paid less to do public work, this is the future of healthcare. He says it's so much more efficient and you can do a lot more work. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Colorectal surgeon Dr Ada Ng from Sydney Adventist Hospital joins John to discuss the importance of testing for bowel cancer, and the symptoms you should keep an eye out for. Listen to John Stanley live on air from 8pm Monday to Thursday on 2GB/4BCSee omnystudio.com/listener for privacy information.

Colorectal cancer is the fourth most common cancer in the U.S. and the second leading cause of cancer death, but what if you could defeat it before it ever has a chance?About one in every 24 people will develop colorectal cancer in their lifetime. And most of the time, your genes are not to blame. So what can you do to lower your risk? First, eat a healthy diet that includes lots of fruits, veggies and whole grains.New research suggests you may also want to up your calcium intake. Researchers found adding 300 milligrams of calcium each day — which is about the amount in a glass of milk — was associated with a 17% lower risk for colorectal cancer.Get regular screenings. Most major organizations suggest you should start at age 45, but not everyone does. Colonoscopies not only look for cancer, they also can help doctors remove precancerous polyps, preventing future cancer.Stop smoking and don't drink in excess. Scientists reported that drinking an additional 20 grams of alcohol daily was linked to a 15% higher risk for colorectal cancer. That's about the amount in a large glass of wine.It's never too soon start.The number of people who have died from colorectal cancer has steadily decreased since the mid 1980s.Experts say this is due to more screening and changing lifestyles.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

June 2, 2025 ~ Donald Trump pledges to raise tariffs on steel. Another Grand Prix weekend is in the books. Colorectal cancer is on the rise among young people. SCOTUS rules Trump can revoke legal status for 500,000 people. Antisemitic terrorist attack in Boulder Colorado and the day's biggest headlines.

In this candid episode, join our hosts as they tackle the critical topic of health, wellness, and burnout in surgery. Drawing from their own personal experiences, they share the practical strategies they use to maintain balance, build resilience, and foster joy both in and out of the operating room.   But this conversation goes beyond coping mechanisms. Our hosts dive deep into the root causes of stress in the surgical profession and explore what it means to proactively design healthier, happier workplaces. They discuss how shifting the focus from individual stress management to eliminating systemic stressors can lead to more sustainable change.

Colorectal cancer rates in adults over the age of 50 have been falling since the 1980s, but that's not the case for young adults. New research shows that colorectal cancer incidences and deaths are increasing in people under 50.If that trend continues, colorectal cancer is expected to become the leading cause of cancer-related deaths among young adults globally by 2030.Delaware Public Media's Kyle McKinnon sits down with Bayhealth colorectal surgeon Dr. Assar Rather to examine the rise in colorectal cancer for young people and how it's being addressed.

Appendiceal neoplasms present with peritoneal carcinomatosis and despite aggressive CRS/HIPEC, often recur and are chemotherapy resistant. In this Colorectal DSWG SSO sponsored podcast episode, we discuss an overview of the recent publication of "Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis with GNAS Mutations" by Dr. Lowy's research lab at UCSD. The authors treated 16 patients in this Phase 2 study of oral Palbociclib in recurrent appendiceal adenocarcinoma patients and identified excellent treatment and long-term response with 13/16 of patients treated having reduction in CEA and excellent survival (median FU of 17.6 months, OS not reached). Dr Lowy provides informative background, study details and discusses next steps for this novel treatment approach. A link to the paper in question is https://pubmed.ncbi.nlm.nih.gov/39413348/

March is National Colorectal Cancer Awareness Month. In this B-Side episode, we dive into everything you need to know about the disease.Colorectal cancer is the fourth leading cause of cancer-related deaths in the Philippines, with an estimated one in 1,800 Filipinos at risk each year. To help understand its symptoms, treatments, and prevention, Dr. Dave Rennel L. Sebollena, Vice President of the Philippine Society of Gastroenterology, joins the conversation.We also explore the financial and healthcare support available for patients with Dr. Israel Francis A. Pargas, Senior Vice President for the Health Finance Sector and Spokesperson of PhilHealth.Interview by Edg Adrian EvaAudio editing by Jayson Mariñas

This isn't your father's colonoscopy. Colorectal screening is entering a new era, with innovations that make the process easier, detection earlier and more accessible than ever. From a simple blood test that can detect signs of cancer to AI technology helping doctors catch polyps that might otherwise go unnoticed, today's tools are transforming the screening experience. Whether you're due for your first test or curious about your options, this conversation offers the insight you need to take charge of your colorectal health — with clarity, confidence and peace of mind.Host:Sandra PeeblesAward-Winning JournalistExperts:Victor Maciel, M.D., Colorectal Surgeon at Baptist HealthAriel Sims, M.D., Gastroenterologist at Gastro Health

The diagnosis of cancer is rising in young adults (

Send us a textMarch is Colorectal Cancer Awareness Month. Colorectal cancer is the fourth most commonly diagnosed cancer in the U.S. and the second leading cause of cancer deaths. Yet this cancer can be prevented with screening and is highly treatable when detected early. On this episode of our DocTalk podcast, we're discussing colon cancer with Dr. Walid Chalhoub, the Division Chief of Gastroenterology at MedStar Southern Maryland Hospital Center, and the Co-Director of Advanced Endoscopy at MedStar Georgetown University Hospital. Dr. Chalhoub discusses the difference between gastroenterology and advanced gastroenterology, and how getting a colonoscopy can save your life.For an interview with Dr. Walid Chalhoub, or for more information about this podcast, contact MedStar Georgetown University Hospital Manager Media Relations, Ryan.M.Miller2@Medstar.net.Learn more about Dr. Chalhoub. For more episodes of MedStar Health DocTalk, go to medstarhealth.org/doctalk.

On the Saturday March 22, 2025 episode of the Richard Crouse Show we meet Emily Diebert. She is a Science Fellow at the Gemini South Observatory in Chile, where she writes children’s books by day and works as an astronomer by night. Her debut novel is “Bea Mullins Takes a Shot,” a novel about a 7th grader who, after being forced to join her school's hockey team discovers unexpected friendships and a budding crush on the team captain. Then, it’s National Colorectal Cancer Awareness Month, a month-long campaign aims to educate Canadians about colorectal cancer and encourage screening. Colorectal cancer is the second leading cause of cancer deaths in Canada but can be effectively treated when detected early. To help me raise awareness is Dr. Peter Stotland, chief of surgery at North York General Hospital and the surgeon who did my colon resection when I was diagnosed with colon cancer twelve years ago.

Colorectal cancer can spread to the liver, and once it does, patients are often at the bottom of the list to receive a liver transplant. But Northwestern Medicine is now offering a new transplant option for select patients that involves splitting a deceased donor liver in two parts. Reset hears from the first patient to undergo this treatment, Barclay Missen, and one of the surgeons Dr. Zachary Dietch. For a full archive of Reset interviews, head over to wbez.org/reset.

In this episode of the Onc Now Podcast, host Jonathan Sackier is joined by Sebastian Stintzing, Head of Department of Medicine, Division of Hematology, Oncology, and Cancer Immunology, Charité - Universitäetsmedizin Berlin, Germany. They discuss the most promising developments in gastrointestinal oncology, with particular focus on the role of personalised medicine in metastatic colorectal cancer treatment.  Timestamps:    00:00 – Introduction  03:04 – Impactful developments in gastrointestinal oncology  08:53 – Issues with funding clinical trials  14:17 – Designing trials and the importance of patient advocacy   17:11 – Translational biomarker programs  19:58 – Treatment strategies for RAS wild-type tumours  22:28 – The FIRE-4.5 study on mutant metastatic colorectal cancer  29:50 – Genetic profiling and epigenomics  33:12 – Precision medicine and immune oncology in GI cancers  34:52 – Colorectal cancer in younger adults  34:54 – Raising awareness for early screening of GI cancers 

Colorectal cancer is one of the most preventable cancers—when caught early. Yet, screening rates remain too low, and cases in younger adults are rising at an alarming rate. Disparities in access to screening also put certain communities at higher risk, making awareness and early detection more critical than ever. In this episode, we're joined by Dr. Reezwana Chowdhury, a leading gastroenterologist at Johns Hopkins and Chair of the American College of Gastroenterology's (ACG) Public Relations Committee. She's also a dedicated advocate for improving awareness in the South Asian community through her work with the South Asian IBD Alliance (SAIA). We cover: Who should get screened and when The rise in early-onset colorectal cancer The connection between IBD and colorectal cancer risk How screening can save your life This episode is presented in collaboration with the American College of Gastroenterology's Patient Care Committee.  

Cette année, une campagne choc a été adoptée pour son titre : "Va ch..."

Cette année, une campagne choc a été adoptée pour son titre : "Va ch..."

Colorectal cancer is the second leading cause of cancer deaths in the U.S. and, alarmingly, rates are rising in younger adults. On this 20-Minute Health Talk, Marc Greenwald, MD, discusses risk factors, symptoms, treatments and the importance of early screening. He also addresses common concerns about colonoscopy, from advances in prep to the lifesaving procedure itself, and helps listeners understand the importance of being proactive about their health.    About the expert Dr. Greenwald is chief of colorectal clinical services; surgeon-in-chief; and director of the rectal cancer program at North Shore University Hospital. About Northwell Health Northwell Health is New York State's largest healthcare provider and private employer, with 21 hospitals, 850 outpatient facilities and more than 16,600 affiliated physicians. We're making breakthroughs in medicine at the Feinstein Institutes for Medical Research. We're training the next generation of medical professionals at the visionary Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and the Hofstra Northwell School of Nursing and Physician Assistant Studies. For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Get the latest news and insights from our experts in the Northwell Newsroom: Press releases Insights Podcasts Publications Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities. Get more expert insights from leading experts in the field — Northwell Newsroom.  Watch episodes of 20-Minute Health Talk on YouTube.  For information on our more than 100 medical specialties, visit Northwell.edu and follow us @NorthwellHealth on Facebook, Instagram, X and LinkedIn. Interested in a career at Northwell Health? Visit http://bit.ly/2Z7iHFL and explore our many opportunities.   Facebook –   / northwellhealth   Instagram -   / northwellhealth   X - https://www.x.com/northwellhealth LinkedIn - https://www.linkedin/northwellhealth

I shared Charlee's journey with Hirschsprung's Disease on Tom's Hirschsprung's Podcast.Charlee has been having ongoing medical issues for a year and a half. We have seen multiple doctors and referred to GI Specialists who ran many tests and procedures but still could not determine the root cause. We were told by multiple doctors that it had nothing to do with her Hirschsprung's Disease. (She was diagnosed at 3 days old and had a life-saving surgery at 8 days old). After doing our own extensive research and finding a community of parents, caretakers, and people with the Disease we found the # 1 recommended  Hirschsprung's Disease doctor in the country, Dr. Wood and reached out to him. We had several phone calls with him and his team prior to our trip to Ohio and they were so knowledgeable and supportive. On September 11th, we traveled to Nationwide Children's Hospital in Columbus, Ohio to see Dr. Wood and the team at the Center for Colorectal and Pelvic Reconstruction (CCPR).  Charlee had an exam under anesthesia where Dr. Wood found that she is missing about 80% of the dentate line. We are grateful for our team at Nationwide and feel supported, finally. We are still processing what the next part of our journey looks like and we're trying to give ourselves grace along the way. To learn more about Charlee's journey, please check out an update video I shared here, www.instagram.com/robyn_lynne. I also plan to share about our experience staying at the Ronald McDonald House while in Ohio. I cannot say enough about how amazing they are. More updates to come! Our girl is so brave, and she will not be defeated.

Ecoutez Ca va beaucoup mieux avec Agathe Landais du 28 février 2025.

Episode 28: 'HAPPY BIRTHDAY HIVESCUM STEVE'Welcome Scummers to the 29th Broadcast From Sump City Radio! Today we celebrate not only the Launch of this episode, but also the Birthday of your host Hivescum Steve.So we asked "Mr Steve, At the ripe old age of 43 what wisdom do you have to share with us?" and after a moment of contemplation, he said the following"Three thing... One. Roll with the punches. For example if you put a project out later than you ideally wanted it to be released and it then happens to fall on a date of celebration, lean into it! make it seem like that was the plan all along!Two. If you start bleeding from places you should not be bleeding, go see a Rogue Doc! Trust me the sooner you do the better you'll be for it. I know it's not fun, but there's enough stuff trying to kill us in The Underhive, don't let your own body be one of them!And three.. I forget what Three was... but just be excellent to each other, the hives already got enough scum and villainy in it, we don't need to add to it.Oh Wait! No.. Three was this.. Believe in the things you enjoy doing! If you believe in it, it doesn't matter what anyone else thinks. You'll find people along the way who DO believe in it and those will be the important people."Wise words indeed.But other than the Sage wisdom of some old fart, we also have The Awesome WELLYWOOD WARGAMING Joining us for..well.. THE ENTIRE SHOW! (We are honoured indeed!)So you get to listen to Hivescum Steve, Underhiver Chris and Damon of Wellywood talking about everything from what they've been up to, what they've seen in the community that's cool and then talking about W.W. and the latest PDF update to VENATORS!Also We read out some letters from you scummers!Additionally we hear from NATOMI SCALTO not once but TWICE as she finally concluded her epic PUBTALE (and buckle in for that one folks, its 1 hour and 25 minutes long!)We also get some solid wisdom from Van Saar Agony Uncle KLAUS VONTHROB.The GOFUNDME set up by Carl Johnston IS STILL LIVE FOR A FEW DAYS! If you would like to help support Hivescum Steve and his family through his treatment and recovery from Colorectal cancer, you can donate here, and much love to you.https://gofund.me/8b37846aNeed a musician to help you with your projects? Go check out MURDER CYBORGS patreon page!⁠ ⁠⁠⁠⁠https://www.patreon.com/murder_cyborg⁠ ⁠⁠⁠ And Tik Tok:⁠ ⁠⁠⁠⁠https://www.tiktok.com/@murder_cyborg⁠⁠⁠⁠⁠ Need help with painting your miniatures? Then please consider ⁠⁠⁠⁠THE UNRELENTING BRUSH⁠⁠⁠ who do international commission painting services, tuition and painting workshops!⁠https://www.theunrelentingbrush.co.uk/⁠CHECK OUT OUR VERY ACTIVE⁠ ⁠⁠DISCORD COMMUNITY⁠⁠⁠!⁠https://discord.com/invite/mGuCwXNHYh⁠CHECK OUT ⁠OUR ⁠SPOTIFY PLAYLIST '⁠⁠Sump City Radio: The Music Hours⁠⁠'⁠⁠. So whether it's for something to listen to whilst playing a game or painting your models, we've got you covered.Almost ALL of the music we use in the show is made by ⁠⁠⁠⁠⁠http://teknoaxe.com⁠ ⁠⁠⁠ or ⁠⁠⁠⁠⁠https://whitebataudio.comTIME STAMPS00:00:00 - INTRO & WELCOME00:24:45 - NATOMI & SCROFULUS PYLE00:31:39 - HOT IN THE HIVE01:31:43 - KLAUS VON THROB, AGONY UNCLE01:39:02 - SHOOTING THE SHIT03:24:08 - PUBTALES, NATOMI'S PART 204:48:50 - YOUR LETTERS & OUTRO

BUFFALO, NY - February 18, 2025 – A new #researchpaper was #published in Oncotarget, Volume 16, on February 12, 2025, titled “Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen." In this study, researchers Doaa A. Gamal, Aiat Morsy, and Mervat Omar from Assiut University Hospital, evaluated a new maintenance treatment for metastatic colorectal cancer (mCRC). Their findings suggest that a combination of two drugs—Panitumumab, a targeted therapy that blocks a protein called epidermal growth factor receptor to slow cancer growth, and low-dose Capecitabine, a chemotherapy drug that converts into 5-fluorouracil (5-FU) inside the body to stop cancer cells from growing and dividing—could help extend survival in patients with mCRC. This regimen appears to be both effective and well-tolerated, especially for patients with wild-type KRAS mCRC who had previously responded to treatment. Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. Standard treatment often involves a combination of chemotherapy and targeted therapies, but many patients face challenges related to treatment toxicity and resistance, which can lead to treatment interruptions. This study tested whether a lower-intensity maintenance treatment could help keep the cancer under control after initial treatment. The study involved 25 mCRC patients with wild-type KRAS and BRAF, who first received six rounds of standard 5-FU-based chemotherapy with Panitumumab. Patients who responded well then switched to a maintenance treatment of Panitumumab every two weeks and a low, continuous dose of Capecitabine. The results showed that patients had a median progression-free survival of 18 months and a median overall survival of 45 months, indicating a strong potential benefit. Patients with metastases detected at the same time as the primary tumor showed a longer progression-free survival than those with metastases appearing later. The treatment was also well tolerated, with only 8% of patients experiencing severe side effects such as skin rash or diarrhea, which were managed with standard treatments. "In our research, the toxicity profile was very acceptable, and no patients needed to stop treatment or had a dose modification due to toxicity." Finding a way to keep cancer under control while reducing side effects is a major goal in cancer treatment. While other maintenance therapies like Bevacizumab and Cetuximab have been studied, this research suggests that Panitumumab with low-dose Capecitabine could be a promising new option. Panitumumab is already an FDA-approved drug, but its role in maintenance therapy had not been extensively explored. The results of this study suggest that this combination may help delay disease progression while keeping side effects manageable, ultimately improving patients' quality of life. Although larger studies are needed, these findings open the door for further clinical trials to confirm the benefits of this regimen. If validated, this approach could change the standard of care for mCRC patients, particularly those who cannot tolerate more intensive chemotherapy. DOI - https://doi.org/10.18632/oncotarget.28687 Correspondence to - Doaa A. Gamal - doaaalygamaal@gmail.com Video short - https://www.youtube.com/watch?v=wuPSS0EdK-8 To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

À l'occasion de la journée mondiale contre cancer, une étude de la fondation ARC met en lumière les freins au dépistage du cancer colorectal. Voici quelles sont les principales résistances et comment les surmonter. Ecoutez Ça va Beaucoup Mieux avec Aline Perraudin du 04 février 2025.

BUFFALO, NY - January 27, 2025 – A new #research paper was #published in Oncotarget's Volume 16 on January 21, 2025, titled “Assessment of cfDNA release dynamics during colorectal cancer surgery." Researchers from the University of Brasília investigated how cell-free DNA (cfDNA) levels in the blood change before, during, and after colorectal cancer surgery. The study found that cfDNA levels increase significantly during and after surgery. The findings suggest that cfDNA could help clinicians evaluate surgery effectiveness and monitor patient outcomes. cfDNA consists of small DNA fragments released into the bloodstream when cells die and break apart. In healthy individuals, cfDNA usually comes from normal cell turnover, while in cancer patients, some of it originates from tumor cells. Measuring cfDNA levels offers valuable insights into a patient's condition and is already being used to track disease progression and treatment response in cancers such as lung, breast, and colorectal cancer. Colorectal cancer is one of the most common cancers worldwide, affecting millions of people each year. Surgery is often the primary treatment, but up to 50% of patients experience cancer recurrence afterward. In this study, the research team, led by first author Mailson Alves Lopes and corresponding author Fabio Pittella-Silva, analyzed blood samples from 30 patients at three key time points: before, during, and after surgery. It was found that cfDNA levels increased nearly threefold during surgery and doubled after surgery compared to pre-surgery levels. The increases were even higher in individuals over 60, those with preexisting conditions such as diabetes or heart disease, and patients with elevated levels of carcinoembryonic antigen (CEA), a common cancer marker. Patients with the highest cfDNA levels were those with larger or more aggressive tumors, likely due to greater tissue damage during surgery. Additionally, longer surgeries were linked to higher cfDNA levels. “[...]we observed that cfDNA concentration may rise in correlation with the duration of the surgery, highlighting its potential as a marker of surgical quality.” These findings suggest that cfDNA could be a valuable, non-invasive biomarker for clinicians to monitor colorectal cancer patients. Tracking cfDNA levels may help better evaluate surgical outcomes and determine whether patients require closer follow-up care. While these findings are promising, further research is needed to standardize cfDNA testing and validate its usefulness. Larger studies could help establish cfDNA testing as a reliable tool for cancer care and postoperative monitoring, with the potential to become a routine part of clinical practice in the future. DOI - https://doi.org/10.18632/oncotarget.28681 Correspondence to - Fabio Pittella-Silva - pittella@unb.br Video short - https://www.youtube.com/watch?v=jC5_xqIrbtA About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Download the FREE Colorectal Cancer Facts and Stats from Fight CRC! Colorectal cancer is becoming increasingly prevalent among individuals under 50. By 2030, it's expected to claim the most lives among this age group, with devastating implications. Currently, Colon cancer is the top cause of cancer death in men and the second in women, trailing only behind breast cancer. Today, we talk about the growing prevalence of colorectal cancer, urging you to take control of your health through lifestyle assessments, screenings, and proactive habits. At the end, we share three actionable steps to kickstart your journey toward better colon health. Our other video on this topic: https://www.youtube.com/watch?v=y9yYu0LOu7Y&t=0s BUY MARK'S BOOK! The Evolving Man: Life Virtues Men Don't Talk About https://bit.ly/TheEvolvingMan USEFUL FINANCIAL TOOLS https://geni.us/new_retirement Use this link for a FREE 14 Day Trial! [Get the FREE Downsizing Guide] How to prepare to downsize your home CHAPTERS: 00:00 Introduction 04:41 Excessive Consumption of Processed Meats 06:28 Not Physically Active 08:10 Smoking 10:56 Lack of Regular Screening 12:44 Review and Adjust Lifestyle Choices CONNECT: Engage in our Free Facebook Community Facebook: /retirementtransformed Instagram: @retirementtransformed LinkedIn: /retirementtransformed Amazon Shop: https://www.amazon.com/shop/retirementtransformed ABOUT RETIREMENT TRANSFORMED Husband and wife duo, Mark & Jody Rollins, inspire and serve as personal guides to meaningful, transformational journeys for individuals who are planning for, going through or are living in retirement. This is everything in retirement beyond your financial plan. We are not financial advisors or medical experts. Any advice we give is our own and should not be taken as professional advice. This video is for informational and entertainment purposes only. Please seek professional assistance before making any financial decisions or changes that can affect your physical or mental health. FTC: Some links mentioned above may be affiliate links, which means we earn a small commission if you buy a product from the specific link. This episode is not sponsored.

Colorectal cancer is the fourth most common cancer in Canada, but screening doesn't begin until age 50. Seeing younger people getting diagnosed, Dr. Shady Ashamalla helped launch Sunnybrook's Young Adult Colorectal Cancer Centre in Toronto. It offers minimally invasive care to patients like Catherine Mifsud, diagnosed with three kids at home in the prime of her career.

In this episode of SurgOnc Today®, Dr. Sinziana Dumitra discusses the evaluation and management of patients with peritoneal metastases from MSI-high colorectal cancer with Dr. Joshua Leinwand and Dr. Zachary Brown, including the role of HIPEC, immunotherapy, and differences in clinical characteristics and outcomes compared with microsatellite-stable disease.

Colorectal cancer, the disease that claimed the life of "Black Panther" actor Chadwick Boseman at age 43, was once considered an “old person's” illness. It no longer is. The National Cancer Institute says early-onset colorectal cancer is now the No. 1 cause of cancer death in people 20 to 49 years old. It gets worse. Studies show that cancer that develops in younger people tends to be more aggressive. So, why are Gen Xers, millennials, and Gen Zers developing a disease they never would have dreamed of getting not that long ago? To help answer this question, I am so honored to be joined by Dr. Andrea Cercek, a board-certified medical oncologist who specializes in the treatment of patients with colorectal cancer (CRC) at Memorial Sloan-Kettering Cancer Center. Dr. Cercek is also the founder and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer – this clinic – dedicated to serving the specific needs of people under 50 who have these cancers, is the first of its kind in the world. In this episode, I talk with Dr. Cercek about the possible causes for this rise in colorectal cancers, what we can do to reduce our risk of developing colorectal cancer, and about the exciting treatment options that are being developed at MSK to cure colorectal cancer without the often-crippling side effects of radiation, chemo, and surgery.  One of the beneficiaries of Dr. Cercek's research and treatment is her former patient, Kelly, who also join us in this conversation. Kelly was just 29 with an 8-month-old baby when she was-diagnosed with colorectal cancer. Thanks to the immunotherapy treatment that Dr. Cercek's team discovered, Kelly is now cancer-free, did not have to have chemo, radiation, or surgery, and has gone on to live a full and healthy life. To learn everything you need to know about colorectal cancer, and to hear one woman's inspiring story, this episode is for you! If you enjoy the show, please rate and review. Be sure to follow us on Instagram @TheInterviewWithLeslie. A new podcast is released every Wednesday.

Featuring perspectives from Dr Christopher Lieu, moderated by Dr Stephen “Fred” Divers CME information and select publications

Behind the Knife ABSITE 2025 – Up-to-date and high yield learning to help you DOMINATE the exam. Don't forget to check out our ABSITE Podcast Companion Book available on Amazon: https://www.amazon.com/Behind-Knife-ABSITE-Podcast-Companion/dp/B0CLDQWZG3/ref=monarch_sidesheet Be sure to check out our brand new free study aid, which includes all 32 review episodes, brief written summaries, high yield images, and flash cards. Simply create an account on our iOS or Android app or on our website and you will find the entire course in your Library. Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Google Play App Store: https://play.google.com/store/apps/details?id=com.btk.app Behind the Knife would like to sincerely thank Medtronic for sponsoring the entire 2025 ABSITE podcast series.  Medtronic has a rich history of supporting surgical education, and we couldn't be happier that they chose to partner with Behind the Knife.  Learn more at https://www.medtronic.com/en-us/index.html If you like the work that Behind the Knife is doing, please leave us a review wherever you listen to podcasts. Visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Behind the Knife ABSITE 2025 – Up-to-date and high yield learning to help you DOMINATE the exam. Don't forget to check out our ABSITE Podcast Companion Book available on Amazon: https://www.amazon.com/Behind-Knife-ABSITE-Podcast-Companion/dp/B0CLDQWZG3/ref=monarch_sidesheet Be sure to check out our brand new free study aid, which includes all 32 review episodes, brief written summaries, high yield images, and flash cards. Simply create an account on our iOS or Android app or on our website and you will find the entire course in your Library. Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049 Google Play App Store: https://play.google.com/store/apps/details?id=com.btk.app Behind the Knife would like to sincerely thank Medtronic for sponsoring the entire 2025 ABSITE podcast series.  Medtronic has a rich history of supporting surgical education, and we couldn't be happier that they chose to partner with Behind the Knife.  Learn more at https://www.medtronic.com/en-us/index.html If you like the work that Behind the Knife is doing, please leave us a review wherever you listen to podcasts. Visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  

Nobody really wants to talk about colorectal health but it's important, nonetheless. This episode is important to me, personally, after losing my mom to colon cancer 13 years ago. I'm joined by colorectal surgeon, Dr. Ritha Belizaire, to talk about not just what you can do to keep you insides healthy, but also how to advocate for yourself at the doctor (no matter what the issue), and how to make leaps of faith to start creating a life you love. Dr. Ritha Belizaire is a dual board certified general and colorectal surgeon and the owner of Houston Community Surgical, a solo private practice in the Houston Heights neighborhood. She is passionate about providing accessible and equitable surgical care to the Greater Houston community. She understands many colorectal related issues are sensitive or embarrassing for patients to discuss, even with their doctors. She aims to provide a safe and inclusive environment for patients to talk about all factors of their colorectal health to ensure the best outcomes for her patients. When she is not working in or on her practice, she loves to spend time with her two daughters, Amelia and Raffaela. LinkedIn - https://www.linkedin.com/in/rithabelizairemd FB -https://www.facebook.com/houstoncommunitysurgical IG - @rithabelizairemd TikTok - @rithabelizairemd Website - https://www.houstoncommunitysurgical.com Subscribe, rate, and review this podcast and get a copy of our Weekend Survival Guide as a thank you! Just email a screenshot of your review to admin@estheravant.com and we'll send it over ASAP! Thanks for your support! Get your Weight Loss That Lasts Cheat Sheet at: https://www.go.estheravant.com/cheatsheet Learn about our 12-week Gone For Good coaching program: www.estheravant.com/coaching Join the Live Diet-Free FB group: www.facebook.com/groups/livedietfree Connect with Esther on Instagram (shoot me a DM and let me know you listen to the podcast!): www.instagram.com/esther.avant

Today, we sit down with Dr. Leigh Erin Connealy, world-renowned medical doctor, leading functional integrative physician, and medical director of Cancer Center for Healing and Center for New Medicine. She uses conventional, homeopathic, Eastern, and modern medicine to address the root cause of medical maladies, including autoimmune disorders and cancer. What are some issues with conventional medicine and prescription drugs? Is it possible to heal cancer naturally? What steps can help prevent cancer? And why is colorectal cancer increasing among young people? Dr. Connealy answers all that and more on how to preserve your health. Get your tickets for Share the Arrows: https://www.sharethearrows.com/ --- Timecodes: (01:07) Dr Connealy's story (16:49) Problems with conventional medicine (22:22) How to lose weight  (32:10) Postpartum weight loss (35:44) Importance of sleep (39:07) Healing & preventing cancer (54:07) Body positivity movement (57:10) Colorectal cancer in young people (1:01:08) Hippocratic oath in medicine (1:05:38) How to find a good doctor --- Today's Sponsors: Seven Weeks Coffee — try Seven Weeks Coffee today at SevenWeeksCoffee.com and use the promo code: ALLIE to save 10% off your order. Covenant Eyes — protect you and your family from the things you shouldn't be looking at online. Go to coveyes.com/ALLIE to try it FREE for 30 days! Carly Jean Los Angeles — use promo code ALLIE50 for $50 off your order of $100+ at carlyjeanlosangeles.com. Birch Gold — protect your future with gold. Text 'ALLIE' to 989898 for a free, zero-obligation info kit on diversifying and protecting your savings with gold. --- Relevant Episodes: Ep 926 | The Secret Reason Doctors Push Cancer Drugs | Guest: Suzy Griswold https://podcasts.apple.com/us/podcast/ep-926-the-secret-reason-doctors-push-cancer-drugs/id1359249098?i=1000640353494 Ep 971 | Question Your Doctor, Save Your Life | Guest: Dr. Casey Means https://podcasts.apple.com/us/podcast/ep-971-doctors-are-paid-to-keep-us-sick-guest-dr-casey-means/id1359249098?i=1000649903503 Ep 693 | The Disturbing Truth About Breast Cancer Awareness Month | Guest: Chris Wark (Chris Beat Cancer) https://podcasts.apple.com/us/podcast/ep-693-the-disturbing-truth-about-breast-cancer/id1359249098?i=1000583065318 --- Buy Allie's book, You're Not Enough (& That's Okay): Escaping the Toxic Culture of Self-Love: https://alliebethstuckey.com/book Relatable merchandise – use promo code 'ALLIE10' for a discount: https://shop.blazemedia.com/collections/allie-stuckey Learn more about your ad choices. Visit megaphone.fm/adchoices